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Background: The underlying mechanisms of carcinogenesis and gender disparity in hepatitis B virus (HBV)-induced
hepatocellular carcinoma (HCC) remain unclear. Recently, we reported a novel HCC-related W4P/R mutation in the
large surface protein (LHB) of HBV genotype C, which was found exclusively in male HCC patients.
Methods: LHB sequences from a carrier (wild type; WT) and W4P variant LHB sequence from an HCC patient were
cloned and used to generate NIH3T3 and Huh7 cell lines. Cell proliferation and in vitro tumorigenicity were assessed by
cell growth and transformation assays. Male and female nude mice were injected with the cells to determine in vivo
tumorigenicity. To confirm the effect of estrogen in W4P-mediated tumorigenicity, male mice were injected with
estrogen and challenged with W4P-expressing cells. The serum levels of different cytokines from the mouse model
and patients were analyzed by ELISA. A critical role of interleukin (IL)-6 signaling in W4P-mediated tumorigenicity was
tested by inhibition of Jak2.
Results: Although both WT and W4P variant LHBs enhanced cell proliferation by regulating the cell cycle and facilitated
cell colony formation, the W4P variant demonstrated significantly higher activity. NIH3T3 cells expressing variant LHB, but
not the WT, induced tumor in a nude mouse model. Tumor masses produced by variant LHB were significantly larger in
male than female mice, and significantly reduced by estrogen. IL-6, but not tumor necrosis factor-α, was elevated in male
mice harboring W4P-induced tumor, and was reduced by estrogen. IL-6 levels of HCC patients with the W4P variant were
significantly higher than those of patients with WT LHB. W4P LHB induced higher production of IL-6 than WT LHB in cell
lines, and the level was reduced by estrogen. The ability to reduce cell proliferation and colony formation of W4P LHB
was hampered by inhibition of IL-6 signaling.
Conclusions: This study suggests that the W4P mutation during the natural course of chronic hepatitis B infection may
contribute to HCC development, particularly in male patients, in an IL-6-dependent manner.
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Hepatitis B virus (HBV) infection is a global health
problem and >350 million people are chronic carriers of
the virus [1,2]. The infection is associated with a wide
spectrum of clinical manifestations, ranging from acute or
fulminant hepatitis to various forms of chronic infection,
including asymptomatic carrier status, chronic hepatitis,
cirrhosis, and hepatocellular carcinoma (HCC) [3,4].
Owing to the successful development of HBV vaccine,
chronic HBV infection in children has been dramatically
reduced worldwide [5,6]. However, adult HBV carriers
still have a significant risk for HCC. In particular, HBV
genotype C, which is found throughout Asia, has a higher
risk for HCC than other genotypes [7,8]. Although the
relationship between HBV infection and HCC develop-
ment is clear, the mechanism by which HBV facilitates
cancer development is not clear. Among the viral fac-
tors, HBV X protein (HBx) is closely related to HCC
development [9-12].
One noteworthy universal epidemiological trait of
HCC is the male predominance, with a male:female ratio
range of 1.5–11:1 [1,13]. The male predominance is more
pronounced in HBV-related than hepatitis-C-virus-related
HCC [14,15]. Both higher androgen levels and more active
androgen receptor gene alleles are correlated with an
increased risk of HCC among male carriers of hepatitis B
surface antigen [16]. Recently, an intriguing interaction
between HBx and the androgen axis in promoting male
HCC was elucidated [17,18].
In addition to the androgen axis, the possible tumor-
protective effect of the estrogen axis for HCC has been
suggested. For example, longer exposure to estrogen, by
taking oral contraceptives or postmenopausal hormone
therapy, in female HBV carriers is associated with a
lower risk of HCC [19]. Moreover, in a diethylnitrosamine-
induced HCC mouse model, estrogen-receptor-α-mediated
inhibition of interleukin (IL)-6 secretion from Kupffer cells
was critical in alleviating the carcinogenic process [20,21].
The role of HBV large surface proteins (LHBs) in the
biology of the virus has yet to be clarified, but it is
suggested that LHBs play a role in virus assembly [22]
and attachment to hepatocytes [23]. Some studies have
proposed that LHBs with mutations in the preS region
contribute to hepatocarcinogenesis through induction of
an endoplasmic reticulum stress pathway or by altering
the transactivating capacity [24-26], which suggests there
may be a disparity in the HCC-inducing capacity between
wild-type (WT) LHBs and the variant with mutations
associated with disease severity.
Recently, through a molecular epidemiological study,
we discovered novel preS1 substitutions (W4P) related
to HCC, in which tryptophan changed to proline at the
fourth codon from the preS1 start [27]. Notably, it occurred
exclusively in male patients. Therefore, we hypothesize thatthe LHB variant with a W4P mutation may contribute to
the male predominance in HCC. To address the hypothesis,
we investigated whether an LHB variant with a W4P
mutation from an HCC patient would exhibit gender
disparity in tumorigenicity.
Results
LHB variant with W4P mutation showed enhanced cell
proliferating activity and facilitated cell cycle progression
To understand the physiological role of W4P mutation
of HBV genotype C, LHB sequences from a carrier (WT)
and a variant LHB sequence with W4P mutation (W4P)
from an HCC patient were cloned. A total of seven
variations between the WT and W4P variant LHB
sequences were found. Three variations were located
in the pre-S1 region, three in the preS2 region, and
two in the S region (Additional file 1: Figure S1).
The W4P variation was related to HCC; therefore, we
examined whether the variation was implicated in cell
growth using mouse NIH3T3 cell lines constitutively
expressing WT LHB (WT-LHB-NIH3T3) and W4P variant
LHB (W4P-LHB-NIH3T3) (Additional file 2: Figure S2).
As shown in Figure 1A, both WT and W4P LHBs
significantly facilitated cell proliferation. Notably, W4P
LHB showed significantly greater enhancement of cell
growth than WT LHB showed. Similar results were
obtained from the experiment using Huh7 human HCC
cell lines expressing vector, WTand W4P LHBs.
LHBs facilitate cell proliferation; therefore, we investigated
whether LHBs regulate cell cycle progression. Expression of
WTand W4P LHB induced 33.5% and 52% increases in the
percentages of cells in S and G2/M phases, respectively
(Figure 1C). The levels of p53 and p21 proteins,
which are associated with the G1/S checkpoint, were
reduced by expression of LHBs, and W4P exerted a
stronger effect than WT (Figure 1D). The levels of
cyclin-dependent kinase (CDK)2, CDK4, cyclin A, and
cyclin D, which are known to be involved in G1/S
transition, were higher in W4P expressing cells than
WT and NIH3T3 cell lines (Figure 1D). These results
suggest that LHBs, especially W4P LHB, regulate cell
cycle progression, and LHBs may affect G1/S transition.
An increase in the well-known proliferation marker
proliferating cell nuclear antigen (PCNA) by W4P
LHB supported the higher cell-proliferating activity of
W4P LHB (Figure 1D).
W4P-LHB-expressing cells had oncogenic potential to
form tumor masses in a mouse model and tumor growth
showed gender disparity
We examined whether W4P mutation was involved in cell
transformation. W4P-LHB-NIH3T3 cells showed a
significantly higher colony forming ability than WT-LHB-
NIH3T3 and NIH3T3 cells. Compared with NIH3T3 cells,
Figure 1 W4P variant LHB facilitates cell proliferation and cell cycle progression. (A and B) Comparison of growth of WT- and
W4P-LHB-expressing NIH3T3 cells (A) and Huh7 cells (B). Cell proliferation was analyzed by cell counting. (C) Influences on cell cycle regulation
by expression of LHBs. The percentage of cells in the G0/G1, S and G2/M phases was assessed by flow cytometry after propidium iodide staining.
(D) Effect of LHBs on cell-cycle-related proteins. Expression of cell-cycle-related proteins in LHB-expressing cells was analyzed by immunoblotting.
R elative amounts of the proteins were analyzed by densitometry using actin as an internal control for normalization (right). The standard
deviations are determined from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 versus NIH3T3 cell line, one-way t test.
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1.9 and 4.6 times, respectively, suggesting that W4P
LHB regulates the cell cycle and has a strong trans-
forming effect on NIH3T3 cells (Figure 2A). Similarly,
W4P-LHB-expressing Huh7 cells lines formed increased
numbers of colonies compared with vector cells or
WT-LHB-expressing cells, suggesting that W4P LHB fa-
cilitates growth of HCC cells (Additional file 3: Figure S3).
To test further whether W4P variation was involved in
tumorigenicity and gender disparity of HCC, we grafted
the cell lines into nude mice. Surprisingly, 19 (10 male
and 9 female) of the 20 mice injected with W4P cells
developed tumors, whereas no tumors were noted in the
groups injected with WT-LHB-NIH3T3 and the control
NIH3T3 cells during the 4 weeks observation period,
indicating that LHB gained oncogenic potential by W4P
mutation (Figure 2B). Although there was no signifi-
cant difference in tumor incidence between male and
female mice, surprisingly, the tumor volume in the
W4P-cell-injected male mice was significantly larger than
in the female mice (Figure 2C). W4P-LHB-induced tumor
showed a typical fasciculated proliferating pattern with
an interstitial collagen matrix (Figure 2D). Most areas
consisted of highly polymorphic, poorly differentiatedspindloid cells with hyperchromatic nuclei. The tumor
cells had an oval vesicular nucleus with two instances
of prominent nucleoli and basophilic cytoplasm. The
mitotic rate was high and apoptotic cells were occasionally
found. Most tumor cells expressed the preS1 antigen in
their cytoplasm (Figure 2D).
W4P-LHB-expressing cells induced production of high
levels of IL-6, especially in male mice
IL-6 is significantly related to gender disparity in hepato-
carcinogenesis [20,21]; thus, we attempted to determine
whether IL-6 was also related to gender disparity in the
tumorigenicity in our W4P-injected mouse model.
Serum IL-6 level in the W4P-injected mice was signifi-
cantly higher than in mice injected with NIH3T3 or WT
(Figure 3A), whereas there was no significant difference
in the level of tumor necrosis factor (TNF)-α (Figure 3B).
Serum IL-6 level of W4P-LHB-NIH3T3-injected mice
was significantly higher in male than in female mice,
suggesting the involvement of IL-6 in gender disparity of
W4P-induced tumor growth (Figure 3A). Supporting
this hypothesis, there was a positive correlation between
IL-6 serum level and tumor size irrespective of gender
(Figure 3C). In line with the mouse data, HCC patients
Figure 2 Transforming activity of W4P variant and gender disparity in tumorigenesis of W4P LHB expressing. (A) Induction of cell
transformation by LHBs. NIH3T3 cells and NIH3T3 cell lines expressing WT and W4P LHBs were subjected to a colony formation assay. Data
represent means ± SD from three independent experiments. **P < 0.01 versus pIRES2-WT, ***P < 0.001 versus NIH3T3 cell line, one-way t test.
(B) Tumor-forming abilities of LHB-expressing cells. Nude mice were injected with NIH3T3 (male, n = 10), WT-LHB-NIH3T3 (WT) (male, n = 10) and
W4P-LHB-NIH3T3 [male (n = 10) and female (n = 10)] cells. The graph shows the tumor incidence of each group. (C) Comparison between male
and female mice in terms of tumor size in nude mice injected with W4P cells. *P < 0.05. (D) Hematoxylin and eosin staining of the tumor mass of
nude mice injected with W4P cells. Expression of LHB was confirmed by immunohistochemical staining using preS1 Ab (AP1).
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IL-6 levels than those carrying WT LHB (Figure 3D),
while there was no significant difference in the level
of TNF-α (Figure 3E).
IL-6 signaling pathway was necessary for cell proliferating
and transforming activities of W4P LHB
We examined the phosphorylation status of signal trans-
ducer and activator of transcription (stat)3, which can be
activated by IL-6 receptor (IL-6R)–Janus kinase (JAK)2
signaling. W4P-LHB-expressing NIH3T3 and Huh7 cells
displayed higher phosphorylation of stat3 than WT-
LHB-expressing cells and parental cells (Figure 4A and
Additional file 4: Figure S4). We took advantage of the
pharmacological inhibition of the IL-6 signaling pathway
by JSI-124, a specific inhibitor of JAK2. Although treat-
ment with JSI-124 reduced the proliferation of both
WT- and W4P-LHB-expressing cells, reduction of W4P-
LHB-expressing cells was much greater than that of
WT-LHB-expressing cells (Figure 4B). The cell trans-
forming activity of W4P was also suppressed by treat-
ment with JSI-124, and there was no significant
difference in the transforming activities of WT- and
W4P-LHB-expressing cells after treatment with JSI-124
(Figure 4C). Suppression of the JAK2–stat3 signaling
axis by siRNAs targeting JAK2 or stat3 resulted in sig-
nificant suppression of W4P-LHB-expressing cell growth
(Figure 4D, 4E).W4P-LHB-mediated IL-6 production and tumor growth
were downregulated by estrogen
W4P-LHB-mediated production of IL-6 is involved in
tumor growth and IL-6 production was significantly
lower in female mice; therefore, we tested the hypothesis
that estrogen signaling may suppress IL-6 production
and inhibit IL-6-mediated tumor growth. Consistent
with the in vivo data, W4P-LHB-NIH3T3 cells produced a
significant amount of IL-6, while the WT-LHB-NIH3T3
and NIH3T3 cells did not produce a detectable amount
of IL-6 (Figure 5A). Treatment with β-estradiol of the
W4P-LHB-NIH3T3 cells resulted in a significant decrease
of IL-6 production (Figure 5A). Co-cultivation of the mur-
ine macrophage cell line J774A with W4P-LHB-NIH3T3
cells resulted in increased production of IL-6, which was
reduced by treatment with estradiol (Figure 5B). Secretion
of IL-6 by J774 was significantly enhanced by treatment of
W4P tumor lysates but not WT tumor lysate, and the level
was lowered by estradiol, suggesting that IL-6 is produced
by W4P-LHB-expressing cells and neighboring macro-
phages (Figure 5C). Consistent with the previous data
showing the crucial role of IL-6–JAK2–stat3 signaling
pathway, treatment with β-estradiol completely abolished
the effect of W4P LHB on cell growth (Figure 5D). In
addition, β-estradiol treatment suppressed phosphorylation
of stat3 in W4P LHB-expressing cells, further supporting
the hypothesis that W4P LHB induced higher cell prolifera-
tion and tumorigenesis (Figure 5E).
Figure 4 Effects of inhibition of IL-6 signaling on proliferation and colony-formation of LHB-expressing cells. (A) Phosphorylated stat3,
stat3 and actin were analyzed by immunoblotting. (B) Designated cells were treated with JSI-124 (10 μM), a Jak2 inhibitor, and their proliferation
was assessed. (C) Colony-forming ability of LHB-expressing cells was examined by a colony forming assay in the absence or presence of JSI-124.
(D and E) Cells were transfected with siRNAs (200 nM) targeting JAK2 (D), stat3 (E) or control scrambled siRNAs as indicated. Cells proliferation
was analyzed by MTT assay. Data represent means ± SD. **P < 0.01, ***P < 0.001.
Figure 3 Induction of IL-6 production by W4P LHB in a gender-dependent manner. (A and B) Serum levels of IL-6 (A) and TNF-α (B)
measured from mice injected with NIH3T3, WT-LHB-NIH3T3 and W4P-LHB-NIH3T3 cells. **P < 0.01, ***P < 0.001. (C) Correlation between serum
IL-6 levels and tumor volumes of W4P-LHB-NIH3T3-injected mice (10 male and 10 female mice) (r = 0.862, P < 0.001). (D and E) Serum IL-6
(D) and TNF-α (E) was measured in 11 HCC patients with WT and 11 with W4P variant sequences. **P < 0.01.
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Figure 5 Effect of estrogen on W4P-LHB-mediated IL-6 production and cell proliferation. (A) Cells were incubated for 48 h with or without
20 nM estradiol. Production of IL-6 was determined by ELISA. (B) J774A.1 cells were co-cultivated with indicated cells for 48 h in the presence or
absence of 20 nM estradiol. (C) J774A.1 cells were treated with 10-mg lysates made from tumors expressing W4P LHB in the presence or absence
of 20 nM estradiol. (D) Cells were treated with vehicle (0.01% ethanol) or 10 nM β-estradiol and subjected to MTT assays. (E) Cells were treated
with vehicle (0.01% ethanol) or 10 nM β-estradiol for 48 h and analyzed by immunoblotting to determine the level of stat3 phosphorylation and
cyclin D. Data represent means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
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tumor growth in male mice (Figure 6A). Treatment of
male mice with β-estradiol drastically reduced the
W4P-LHB-expressing tumor incidence. In the control
group, six of eight mice developed tumor, whereas one of
10 mice developed tumor in the β-estradiol-treated group,
and the tumor size was smaller than the average value in
the PBS-treated group (Figure 6B, 6C). Four weeks
after injection, the serum levels of IL-6 and TNF-α
were determined. β-Estradiol significantly decreased serum
IL-6 level by >60% compared with the PBS-treated group
(Figure 6D). Serum TNF-α levels between the two nude
mice groups did not differ significantly (Figure 6E). Taken
together, our data strongly suggest that IL-6 plays a pivotal
role in tumorigenicity and growth of W4P-expressing
cells, and estrogen is capable of suppressing W4P-LHB-
mediated tumorigenicity and tumor growth.
Discussion
South Korea is still a high-endemic area for HBV
infection, and HCC is more prevalent by 4.2–5.9 times in
men than in women [28,29]. This male-to-female
ratio of HCC incidence is higher than the average of
2.9:1 worldwide [30], which suggests that there are
crucial viral factors in Korean chronic HBV patients
favoring a male predominance. In an effort to deter-
mine HBV mutation types that contribute to gender
disparity in HCC, we recently discovered the W4P/Rmutation, which is found only in men, using a molecular
epidemiological approach.
We selected W4P LHB and WT LHB from an HCC
patient and a carrier with or without W4P mutation,
respectively [27]. Sequence comparison between W4P
LHB and WT LHB showed that there were seven variations
including W4P. However, in our careful inspection of the
literature, we did not find any notable mutations, except for
W4P, related to liver disease severity. Thus, although the
acquisition of W4P mutation is likely to affect mostly the
tumorigenic nature of variant LHB, the synergistic or
additive effect of other variations cannot be excluded.
In this study, we demonstrated that the expression of
LHBs enhanced cell proliferation and W4P LHB exerted
a stronger effect. Expression of W4P LHB resulted in
downregulation of the p53 pathway. It is likely that W4P
LHB impairs the cell-cycle checkpoint at the G1/S phase
by inhibiting the p53–p21 axis, which in turn may
contribute to HCC by the accumulation of mutations
due to the maintenance of genome stability. Cyclin A
plays an important role in the S and G2/M phases of the
cell cycle [31]. It should be noted that W4P LHB upre-
gulates expression of cyclin A in hepatocytes, because it
is overexpressed in HCC tissue [32,33]. The enhanced
colony-forming capability of W4P LHB provides further
support for the potential role of the W4P mutation in
HBV-related hepatocarcinogenesis. Similar patterns were
observed in W4P-LHB-expressing Huh7 HCC cell lines.
Figure 6 Suppression of W4P-mediated tumorigenicity by estrogen. (A) Scheme of the experiment. Male mice were injected with 0.5 mg/kg
β-estradiol or PBS. One week later, mice were injected with W4P-LHB-expressing cells subcutaneously together with 0.5 mg/kg β-estradiol or PBS.
Mice were injected with 0.5 mg/kg β-estradiol or PBS twice weekly. Tumor incidence (B) and tumor volume (C) were determined. (D and E) Serum
IL-6 (D) and TNF-α (E) levels in mice were determined using a Bio-Plex cytokine panel (BioRad) and Luminex 200 (Luminex). **P < 0.01.
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in the LHB region, such as W4P, during the natural
course of chronic hepatitis B, may contribute to
HCC generation. This strongly supports the previous
epidemiological finding showing a higher prevalence
of W4P mutation in patients with severe forms of
liver disease than in those with milder forms of liver
disease [27].
HBx contributes to gender disparity in HBV infection or
HCC generation mainly due to signaling via the androgen
axis [18,34,35]. However, although it is important for the
initial replication in the host, it is not essential for HBV
life cycle or chronic infection, so its function has been lost
occasionally in chronic patients during the course of
chronic hepatitis B via deletion events [34,36]. Therefore,
another viral factor providing a likely explanation of
gender disparity in HCC generation, mainly in the final
stage of chronic hepatitis B, should be considered. Our
in vivo mouse data clearly proved that W4P LHB, but notWT LHB, had higher potential for tumor formation in
male than in female mice, suggesting mutations in LHB,
such as W4P, occurring in a later stage of chronic hepatitis
B, could contribute to the gender disparity in HCC
generation.
Our in vivo data also showed that the gender disparity
in W4P-LHB-induced tumorigenicity was closely related
to the difference in IL-6 production between the
genders. IL-6 is known to play a crucial role in the fibro-
sis and HCC related to liver regeneration [20,21,37].
Moreover, HCC patients with W4P variant displayed a
higher IL-6 serum level than HCC patients with WT.
The NIH3T3 cell line constitutively expressing W4P
LHB induced preferential tumor formation in male nude
mice over females, as well as having oncogenic potential
at a high level, with 95% tumor generation incidence
within 4 weeks. Our in vivo system showed a significant
positive correlation between tumor size and IL-6 secre-
tion, supporting previous reports regarding the positive
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shown to evoke biological defense against hepatocarci-
nogenesis by functioning as a negative regulator of IL-6
production in liver Kupffer cells [37]. In our study, we
showed that estrogen suppressed production of IL-6 and
subsequently reduced W4P-induced tumor growth in
male mice, which suggests that a high level of estrogen
in female mice suppresses tumorigenesis by W4P variant
HBV through regulating IL-6 signaling. Thus, a likely
explanation of the preponderance of tumor generation
in male mice observed in our W4P-injected mouse
model is that female hormonal factors play a suppressive
role in W4P-induced tumorigenicity by inhibiting IL-6
production. Several studies have shown the relation
between menopause and HCC risk in women. For
example, a 1-year delay in the onset of menopause
reduced the risk of HCC by 21%, and hormone re-
placement therapy was associated with a low risk of
HCC [38,39]. Our data provide some insights and expla-
nations for the gender disparity in HCC and how estrogen
suppresses, at least in part, the tumorigenicity induced by
HBV mutations.
Conclusions
The novel HBV preS1 mutation W4P may contribute to
HCC development in men with chronic hepatitis B in an
IL-6-dependent manner. This is believed to be the first
report showing direct involvement of HBV LHBs in
gender disparity of tumorigenesis. This study provides a
new insight into understanding the reason behind the
male predominance of HCC in chronic hepatitis B
patients. Our data showing an inhibitory effect of estrogen
in tumor formation in male nude mice suggest that estro-
gen or estrogenic compounds have therapeutic potential
in patients with W4P-LHB-induced HCC.
Methods
Generation of stable cell lines
Sequences encoding WT and variant LHBs were amplified
from a patient with HBV carrier status and an HCC
patient, which were proven without and with W4P/R
mutation by a real-time polymerase chain reaction
method as described previously [27]. Amplified products
were cloned into the pIRES2 vector. NIH3T3 murine cell
lines and Huh7 human HCC cell lines constitutively
expressing the WT LHB and W4P variant were estab-
lished by transfection with pIRES2-WT or pIRES2-W4P,
followed by the selection with 500 μg/ml neomycin.
Analysis of cell proliferation and cell cycle
To analyze the proliferation of cells, 104 cells were seeded
on 100-mm tissue culture dishes. The number of viable
cells was determined at each time point by counting after
trypan blue staining. To analyze the cell cycle, the DNAcontent of cells was assessed via propidium iodide
staining, followed by flow cytometry. To analyze the
role of JAK2 and stat3, cells were transfected with
siRNAs targeting them (Bioneer, Daejeon, Korea) and
subjected to conventional 3-(4, 5)-dimethylthiazol (−z-y1)-
diphenyltetrazolium bromide (MTT) cell viability assay.
Colony-forming assay
One hundred cells of each cell line were seeded in a
six-well culture plate. After incubation for 14 days,
colonies were fixed and stained with 0.5% methylene
blue in ethanol for 10 min at room temperature. The
number of cell colonies in each dish was counted
under a microscope.
Immunoblot analysis
Anti-preS1 (Aprogen, Daejeon, Korea), anti-cyclin A,
anti-cyclin D1, anti-cdk2, anti-cdk4, anti-PCNA (Abcam,
Cambridge, UK), anti-p53 and anti-β-actin (Santa Cruz
Biotechnology Santa Cruz, CA, USA) antibodies were
used for immunoblotting.
ELISA
The amounts of secreted IL-6 and TNF-α were deter-
mined by mIL-6 and TNF-α ELISA kits (eBioscience,
San Diego, CA, USA). The cells were incubated for
48 h and the supernatants were subjected to ELISA.
To investigate the effect of estradiol on secretion of
IL-6, cell lines were treated with 20 nM β-estradiol
for 48 h. To examine the secretion of cytokines by macro-
phages, J774A.1 cells were incubated in the presence or
absence of W4P-LHB-expressing tumor homogenate
(10 mg) for 48 h with or without 20 mM estrogen.
In vivo tumorigenicity study
About 107 NIH3T3, WT-LHB-NIH3T3 and W4P-LHB-
NIH3T3 cells were injected subcutaneously into the
right hind legs of 8-week-old nude mice. Tumor forma-
tion was monitored over a 4-week period. Tumor volumes
were calculated using the following equation: length ×
(width)2 × 0.52. The resected tumor masses were fixed and
processed in an alcohol–xylene series followed by paraffin
embedding. For histological examination, sections were
stained with hematoxylin and eosin or subjected to immu-
nohistochemistry with anti-preS1 monoclonal antibodies.
To examine the effect of estrogen on tumor growth,
male mice were injected with β-estradiol (0.5 mg/kg)
or PBS. One week later, mice were injected with
W4P-LHB-NIH3T3 cells subcutaneously together with
β-estradiol (0.5 mg/kg) or PBS injection. Mice were
injected with β-estradiol (0.5 mg/kg) or PBS twice weekly.
Serum IL-6 and TNF-α levels were determined using a
Bio-Plex cytokine panel (BioRad, CA). All of the animal
experiments were conducted following NIH guidelines for
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with the protocol approved by Institutional Animal Care
and Use Committee (IAUAC) of Seoul National University
College of Medicine (protocol number SNU-111025).
Patients
Sera from 22 male HCC and liver cirrhosis patients with
WT and W4P LHBs were subjected to multiplex cyto-
kine measurement. Patients information was previously
described [27]. The Ethical Committee of Seoul National
University Hospital (IRB No. C-1007-021-322) approved
this research protocol and waived the need for written
informed consent because routine diagnostic data were
analyzed anonymously (Additional file 5: Table S1).
Statistical analysis
All ELISA and cell proliferation assays in this study were
repeated at least three times, and the results were
expressed as percentages, means ± SD, or as medians
(range). Differences between categorical variables were
analyzed using Fisher’s exact test or χ2 test. For continu-
ous variables, Student’s t test was used when the data
showed a normal distribution, or the Mann–Whitney
U test was used when the data were not normally dis-
tributed. A value of P < 0.05 (two-tailed) was considered to
be statistically significant.
Additional files
Additional file 1: Figure S1. WT and W4P variant LHB DNAs were
cloned from a HBV carrier and a HCC patient, respectively. The amino
acid sequences of the preS1 region from the reference strain (genotype
A, B, C, and D) were aligned. (B) NIH3T3 cells stably expressing WT and
W4P LHBs were established. Expression of LHBs were confirmed by
immunoblotting with an anti-preS1 antibody.
Additional file 2: Figure S2. NIH3T3 (left) and Huh7 (right) cell lines
stably expressing WT and W4P LHBs were established. Expression of LHBs
were confirmed by immunoblotting with an anti-preS1 antibody.
Additional file 3: Figure S3. Induction of cell transformation by LHBs.
Huh7 cell lines expressing WT and W4P LHBs were subjected to a colony
formation assay. Data represent means ± SD from three independent
experiments. *** P < 0.001 vs vector cell line, 1-way t-test.
Additional file 4: Figure S4. Phosphorylation of stat3 and expression
of proliferation related proteins of vector, WT-LHB or W4P LHB Huh7 cell
lines were analyzed by immunoblotting.
Additional file 5: Table S1. Clinical factors of patients.
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